Hope in action: a clinical trial of HIV-to-HIV liver transplantation

Active Cooperative Agreement Awarded Last action

Award ID
U01AI138897
Recipient
Awarding agency
Obligated
$66,952,747

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 68% complete
Originally
Funding
  • $56,529,136.00 Federal
  • $10,423,611.00 Non-federal
Place of performance
Baltimore, MD 21205, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment Expanding hope liver transplantation: understanding opportunistic infection and cancer risk - early studies of liver transplantation (LT) from donors with HIV… $1,581,257
Amendment $0
Amendment Hope in action: a clinical trial of HIV-to-HIV liver transplantation - end-stage liver disease is common in HIV-infected (HIV+) individuals due to… $0
Amendment $0
Amendment $0
Amendment $1,683,861
Amendment $1,683,861
Amendment $0
Amendment Expanding hope liver transplantation: understanding opportunistic infection and cancer risk - early studies of liver transplantation (LT) from donors with HIV… $0
Amendment Hope in action: a clinical trial of HIV-to-HIV liver transplantation - end-stage liver disease is common in HIV-infected (HIV+) individuals due to… $0
Amendment Expanding hope liver transplantation: understanding opportunistic infection and cancer risk - early studies of liver transplantation (LT) from donors with HIV… $0
Amendment Hope in action: a clinical trial of HIV-to-HIV liver transplantation - end-stage liver disease is common in HIV-infected (HIV+) individuals due to… $0
Amendment Expanding hope liver transplantation: understanding opportunistic infection and cancer risk - early studies of liver transplantation (LT) from donors with HIV… $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $6,700,000
Amendment $6,700,000
Amendment $6,700,000
Amendment Hope in action: a clinical trial of HIV-to-HIV liver transplantation - end-stage liver disease is common in HIV-infected (HIV+) individuals due to… $0
Amendment Covid protection after transplant (cpat) multicenter adaptive trial - solid organ transplant recipients experience high mortality from covid-19 due to a… $0
Amendment $0
Amendment $0
Amendment Hope in action: a clinical trial of HIV-to-HIV liver transplantation - end-stage liver disease is common in HIV-infected (HIV+) individuals due to… $0
Amendment Covid protection after transplant (cpat) multicenter adaptive trial - solid organ transplant recipients experience high mortality from covid-19 due to a… $0
Amendment $0
Amendment Hope in action: a clinical trial of HIV-to-HIV liver transplantation - end-stage liver disease is common in HIV-infected (HIV+) individuals due to… $0
Amendment Covid protection after transplant (cpat) multicenter adaptive trial - solid organ transplant recipients experience high mortality from covid-19 due to a… $0
Amendment Hope in action: a clinical trial of HIV-to-HIV liver transplantation - end-stage liver disease is common in HIV-infected (HIV+) individuals due to… $0
Amendment $0
Amendment $0
Amendment Covid protection after transplant (cpat) multicenter adaptive trial - solid organ transplant recipients experience high mortality from covid-19 due to a… $0
Amendment Covid protection after transplant (cpat) multicenter adaptive trial - end-stage liver disease is common in HIV-infected (HIV+) individuals due to CO-infection… $0
Amendment $0
Amendment $0
Amendment Covid protection after transplant (cpat) multicenter adaptive trial - solid organ transplant recipients experience high mortality from covid-19 due to a… $126,471
Show 40 more

Latest 50 listed here. See the rest on GovTribe.

Subawards

Subrecipient Amount Awarded
New York University Expanding HOPE Liver Transplantation: Understanding Opportunistic Infection and Cancer Risk $81,026
The Regents Of The University Of California. San Francisco HOPE in Action: A Clinical Trial of HIV to HIV Liver Transplantation $43,650
Yale New Haven Hospital, Inc. COVID Protection After Transplant (CPAT) Multicenter Adaptive Trial $48,160
University Of California, San Diego Safety and Immunogenicity of a dose of the Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine in kidney transplant recipients with a suboptimal… $92,750
University Of Illinois $95,834
IUP Research Institute COVID Protection After Transplant (CPAT) Multicenter Adaptive Trial $136,842
Weill Medical College Of Cornell University $6,941,821
Emory University $65,785
Georgetown University $35,050
Icahn School Of Medicine At Mount Sinai $186,257
New York University $799,043
Icahn School Of Medicine At Mount Sinai $112,275
New York University $599,932
The University Of Iowa $66,284
New York University $141,178
The Regents Of The University Of California. San Francisco $83,840
Ochsner Clinic Foundation $77,188
New York University $61,250
The Methodist Hospital $77,188
University Of Pittsburgh - Of The Commonwealth System Of Higher Education $61,250
University Of California, San Diego $3,000
Emory University $113,186
University Of Wisconsin System $62,265
Icahn School Of Medicine At Mount Sinai $144,718
Show all 24

Quick answers

Who received award U01AI138897?

U01AI138897 was awarded to The Johns Hopkins University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 1, 2018.

How much is award U01AI138897 worth?

$66,952,747 has been obligated on U01AI138897: $56,529,136 in federal funding and $10,423,611 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login